Thomas Cable Sells 15,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) Director Thomas Cable sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the transaction, the director owned 35,067 shares in the company, valued at $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Omeros Stock Performance

OMER stock opened at $19.27 on Friday. The company has a market capitalization of $1.39 billion, a PE ratio of 15.05 and a beta of 2.54. Omeros Corporation has a one year low of $3.94 and a one year high of $19.58. The company’s 50 day moving average price is $11.73 and its two-hundred day moving average price is $11.76.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. On average, research analysts predict that Omeros Corporation will post -0.37 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OMER. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Trading of Omeros

Institutional investors have recently modified their holdings of the company. State of Wyoming bought a new stake in shares of Omeros in the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros during the 4th quarter valued at approximately $33,000. Assetmark Inc. bought a new position in Omeros during the 1st quarter valued at approximately $38,000. Arax Advisory Partners lifted its holdings in Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 1,894 shares during the period. Finally, International Assets Investment Management LLC lifted its holdings in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 800 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.